WO2007023808A1 - 皮膚老化マーカーとその利用技術 - Google Patents
皮膚老化マーカーとその利用技術 Download PDFInfo
- Publication number
- WO2007023808A1 WO2007023808A1 PCT/JP2006/316407 JP2006316407W WO2007023808A1 WO 2007023808 A1 WO2007023808 A1 WO 2007023808A1 JP 2006316407 W JP2006316407 W JP 2006316407W WO 2007023808 A1 WO2007023808 A1 WO 2007023808A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- keratin
- protein
- skin
- expression
- galectin
- Prior art date
Links
- 230000009759 skin aging Effects 0.000 title claims abstract description 82
- 238000000034 method Methods 0.000 title claims abstract description 58
- 239000003550 marker Substances 0.000 title abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 285
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 254
- 230000014509 gene expression Effects 0.000 claims abstract description 157
- 210000003491 skin Anatomy 0.000 claims abstract description 84
- 230000003834 intracellular effect Effects 0.000 claims abstract description 69
- 230000032683 aging Effects 0.000 claims abstract description 61
- 239000000126 substance Substances 0.000 claims abstract description 57
- 210000004927 skin cell Anatomy 0.000 claims abstract description 43
- 102100040443 Keratin, type I cytoskeletal 15 Human genes 0.000 claims description 31
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 claims description 31
- 108010066330 Keratin-15 Proteins 0.000 claims description 30
- 108010070507 Keratin-7 Proteins 0.000 claims description 30
- 102100034867 Kallikrein-7 Human genes 0.000 claims description 29
- 101710176222 Kallikrein-7 Proteins 0.000 claims description 29
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 claims description 29
- 108010065038 Keratin-10 Proteins 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 26
- 102000000802 Galectin 3 Human genes 0.000 claims description 23
- 108010001517 Galectin 3 Proteins 0.000 claims description 23
- 108010001498 Galectin 1 Proteins 0.000 claims description 22
- 102100021736 Galectin-1 Human genes 0.000 claims description 22
- 108090000668 Annexin A2 Proteins 0.000 claims description 21
- 102000004878 Gelsolin Human genes 0.000 claims description 21
- 108090001064 Gelsolin Proteins 0.000 claims description 21
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims description 21
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims description 21
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 21
- 108010066327 Keratin-18 Proteins 0.000 claims description 21
- 102100027869 Moesin Human genes 0.000 claims description 21
- 108010071525 moesin Proteins 0.000 claims description 21
- 102000044465 Galectin-7 Human genes 0.000 claims description 20
- 101000608772 Homo sapiens Galectin-7 Proteins 0.000 claims description 20
- 102100040487 Keratin, type I cytoskeletal 13 Human genes 0.000 claims description 20
- 108010066321 Keratin-14 Proteins 0.000 claims description 20
- 108010066302 Keratin-19 Proteins 0.000 claims description 20
- 108010066370 Keratin-20 Proteins 0.000 claims description 20
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 20
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 20
- 102100022127 Radixin Human genes 0.000 claims description 20
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims description 20
- 108010048484 radixin Proteins 0.000 claims description 20
- 102000004149 Annexin A2 Human genes 0.000 claims description 19
- 108010065070 Keratin-13 Proteins 0.000 claims description 19
- 108010066364 Keratin-16 Proteins 0.000 claims description 19
- 102100038910 Alpha-enolase Human genes 0.000 claims description 18
- 102100020903 Ezrin Human genes 0.000 claims description 18
- 108010091175 Matriptase Proteins 0.000 claims description 18
- 108010055671 ezrin Proteins 0.000 claims description 18
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 claims description 17
- 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 claims description 17
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 claims description 17
- 101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 claims description 17
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 17
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 17
- 101710165425 Alpha-enolase Proteins 0.000 claims description 16
- 101710184673 Enolase 1 Proteins 0.000 claims description 16
- 108020004999 messenger RNA Proteins 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 102000011782 Keratins Human genes 0.000 claims description 12
- 108010076876 Keratins Proteins 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 9
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 8
- 108010017007 glucose-regulated proteins Proteins 0.000 claims description 8
- -1 PAI— 1 Proteins 0.000 claims description 7
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 6
- 239000002853 nucleic acid probe Substances 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 101001095095 Homo sapiens Proline-rich acidic protein 1 Proteins 0.000 claims description 4
- 102000013566 Plasminogen Human genes 0.000 claims description 4
- 108010051456 Plasminogen Proteins 0.000 claims description 4
- 108091058545 Secretory proteins Proteins 0.000 claims description 4
- 102000040739 Secretory proteins Human genes 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 claims 5
- 102100040441 Keratin, type I cytoskeletal 16 Human genes 0.000 claims 5
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 claims 5
- 102000018329 Keratin-18 Human genes 0.000 claims 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 1
- 102100023915 Insulin Human genes 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 208
- 210000004027 cell Anatomy 0.000 description 77
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 49
- 210000001519 tissue Anatomy 0.000 description 49
- 238000010790 dilution Methods 0.000 description 32
- 239000012895 dilution Substances 0.000 description 32
- 150000001413 amino acids Chemical group 0.000 description 26
- 230000037303 wrinkles Effects 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 210000000434 stratum corneum Anatomy 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 20
- 238000001262 western blot Methods 0.000 description 20
- 230000008859 change Effects 0.000 description 19
- 230000003247 decreasing effect Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 17
- 102000018332 Keratin-14 Human genes 0.000 description 15
- 102000057615 Keratin-20 Human genes 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 102000018280 Keratin-16 Human genes 0.000 description 14
- 102100021238 Dynamin-2 Human genes 0.000 description 13
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 230000009758 senescence Effects 0.000 description 12
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 102000035195 Peptidases Human genes 0.000 description 11
- 108091005804 Peptidases Proteins 0.000 description 11
- 239000013592 cell lysate Substances 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- 239000004365 Protease Substances 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 9
- 210000000981 epithelium Anatomy 0.000 description 9
- 210000003963 intermediate filament Anatomy 0.000 description 9
- 235000019419 proteases Nutrition 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102100025614 Galectin-related protein Human genes 0.000 description 8
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000007665 sagging Methods 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 239000002033 PVDF binder Substances 0.000 description 7
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 7
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 7
- 230000032677 cell aging Effects 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 5
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 5
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 5
- 101710113864 Heat shock protein 90 Proteins 0.000 description 5
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 5
- 108010070514 Keratin-1 Proteins 0.000 description 5
- 108010026552 Proteome Proteins 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 102100039328 Endoplasmin Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102100025759 Keratin, type II cytoskeletal 3 Human genes 0.000 description 4
- 108010070918 Keratin-3 Proteins 0.000 description 4
- 108010085895 Laminin Proteins 0.000 description 4
- 102000007547 Laminin Human genes 0.000 description 4
- 239000000538 analytical sample Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000007563 Galectins Human genes 0.000 description 3
- 108010046569 Galectins Proteins 0.000 description 3
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 3
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 3
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 3
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 3
- 108010070553 Keratin-5 Proteins 0.000 description 3
- 108010070511 Keratin-8 Proteins 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 3
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 3
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010005173 SERPIN-B5 Proteins 0.000 description 3
- 102100030333 Serpin B5 Human genes 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000018472 Type I Keratins Human genes 0.000 description 3
- 108010091525 Type I Keratins Proteins 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 108010028309 kalinin Proteins 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000000751 protein extraction Methods 0.000 description 3
- 239000003001 serine protease inhibitor Substances 0.000 description 3
- 238000007390 skin biopsy Methods 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 102000000412 Annexin Human genes 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- 102100034613 Annexin A2 Human genes 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 240000003550 Eusideroxylon zwageri Species 0.000 description 2
- 101150096839 Fcmr gene Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 102000018331 Keratin-17 Human genes 0.000 description 2
- 108010066325 Keratin-17 Proteins 0.000 description 2
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101710180319 Protease 1 Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 description 2
- 101710102218 Serine protease inhibitor Proteins 0.000 description 2
- 241001522306 Serinus serinus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 2
- 239000007997 Tricine buffer Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000010094 cellular senescence Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000003741 urothelium Anatomy 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- CFBILACNYSPRPM-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(N)(CO)CO.OCC(CO)(CO)NCC(O)=O CFBILACNYSPRPM-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- 125000002124 5'-adenosyl group Chemical group N1=CN=C2N(C=NC2=C1N)[C@H]1[C@H](O)[C@H](O)[C@H](O1)C* 0.000 description 1
- 125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- MPVDXIMFBOLMNW-ISLYRVAYSA-N 7-hydroxy-8-[(E)-phenyldiazenyl]naphthalene-1,3-disulfonic acid Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1\N=N\C1=CC=CC=C1 MPVDXIMFBOLMNW-ISLYRVAYSA-N 0.000 description 1
- 108091005508 Acid proteases Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101000640990 Arabidopsis thaliana Tryptophan-tRNA ligase, chloroplastic/mitochondrial Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004958 Caspase-14 Human genes 0.000 description 1
- 108090001132 Caspase-14 Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 101800004419 Cleaved form Proteins 0.000 description 1
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 description 1
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- 102000012193 Cystatin A Human genes 0.000 description 1
- 108010061641 Cystatin A Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 229940094664 Cysteine protease inhibitor Drugs 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 238000009014 DC Assay Kit Methods 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001669679 Eleotris Species 0.000 description 1
- 102100031334 Elongation factor 2 Human genes 0.000 description 1
- 102100026761 Eukaryotic translation initiation factor 5A-1 Human genes 0.000 description 1
- 102000010111 Ezrin/radixin/moesin Human genes 0.000 description 1
- 108050001788 Ezrin/radixin/moesin Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 101710093554 Galactose-specific lectin Proteins 0.000 description 1
- 108010036164 Glutathione synthase Proteins 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000005623 HSP27 Heat-Shock Proteins Human genes 0.000 description 1
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 102100040352 Heat shock 70 kDa protein 1A Human genes 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- 101710100504 Heat shock protein beta-1 Proteins 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000812663 Homo sapiens Endoplasmin Proteins 0.000 description 1
- 101001037759 Homo sapiens Heat shock 70 kDa protein 1A Proteins 0.000 description 1
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 1
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 101710183404 Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- 101710183403 Keratin, type I cytoskeletal 13 Proteins 0.000 description 1
- 101710183392 Keratin, type I cytoskeletal 15 Proteins 0.000 description 1
- 108050006944 Keratin, type I cytoskeletal 18 Proteins 0.000 description 1
- 101710183399 Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 102100023129 Keratin, type I cytoskeletal 9 Human genes 0.000 description 1
- 102100022854 Keratin, type II cytoskeletal 2 epidermal Human genes 0.000 description 1
- 102100025758 Keratin, type II cytoskeletal 4 Human genes 0.000 description 1
- 101710194919 Keratin, type II cytoskeletal 7 Proteins 0.000 description 1
- 108010070520 Keratin-2 Proteins 0.000 description 1
- 108010070921 Keratin-4 Proteins 0.000 description 1
- 108010070557 Keratin-6 Proteins 0.000 description 1
- 102000005706 Keratin-6 Human genes 0.000 description 1
- 108010070585 Keratin-9 Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 101710197058 Lectin 7 Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 description 1
- 102100036518 Nucleoside diphosphate phosphatase ENTPD5 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
- 102100029139 Peroxiredoxin-1 Human genes 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010042135 Stomatitis necrotising Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 1
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 102000002501 Tryptophan-tRNA Ligase Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010082433 UDP-glucose-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- 102100029163 Ubiquitin carboxyl-terminal hydrolase 14 Human genes 0.000 description 1
- 101710091086 Ubiquitin carboxyl-terminal hydrolase 14 Proteins 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000288 anti-kallikrein effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 108010022937 endoplasmin Proteins 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 108010085279 eukaryotic translation initiation factor 5A Proteins 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 108010028546 nucleoside-diphosphatase Proteins 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000000955 peptide mass fingerprinting Methods 0.000 description 1
- 108030002458 peroxiredoxin Proteins 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical group OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102000011843 rho-Specific Guanine Nucleotide Dissociation Inhibitors Human genes 0.000 description 1
- 108010036036 rho-Specific Guanine Nucleotide Dissociation Inhibitors Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to a skin aging marker and a technique for using the same.
- SA- ⁇ -Gal senescence—associated ⁇ -galactosidase
- SA— ⁇ Gal is not expressed in terminally differentiated cells but only in senescent cells. It was revealed that it is specifically expressed and correlates very well with aging in human skin tissue (Non-patent Document 6).
- Other skin aging markers such as Maspin, a serine protease inhibitor, and Cyatatin A, a cysteine protease mhi bitor have been reported (Non-patent Documents 7 and 8).
- proteome As a method to search for biomarkers of skin aging, when a specific cell is placed under specific conditions, the total protein (proteome) present in the cell is separated by two-dimensional electrophoresis, and then analyzed by a mass spectrometer. Proteomics are useful. In fact, proteins from young and aged human skin tissues were also extracted, and proteins that were significantly changed by proteomics due to skin aging eIF-5A, Cyclophilin A, Proteasomal protein, PA28-, Tryptophanyl-tRNA synthetase ⁇ HSP60, Annexin
- Non-patent Document 9 the proteomics carried out on the skin so far is an analysis using an extract of skin tissue or a cell extract, and the proteomics were performed focusing on cell culture supernatants containing a large amount of secreted proteins. There is no example.
- verification of the identified skin aging marker in human skin is a less practical method such as immunostaining on skin tissue removed by Neuropsi, and it is safe and simple to collect the stratum corneum non-invasively.
- a stratum corneum can be collected using a horny checker that can extract the protein from the stratum corneum, and it is highly practical to examine the expression of a skin aging marker.
- Patent Document 2 Japanese Patent Laid-Open No. 2002-360544
- Patent Document 3 Japanese Patent Laid-Open No. 2001-212087
- Non-Patent Document 1 Clinic. Invest., 114, 1299-1307, 2004
- Non-Patent Document 2 Mol. Cell. Biochem. 1999 Apr, 194 (1—2): 99—108
- Non-Patent Document 3 J. Investig. Dermatol. Symp. Proc., 3 (2), 172-179, 1998
- Non-Patent Document 4 Mech. Aging Dev., 123 (7), 801-810, 2002.
- Non-Patent Document 5 Gerontology, 55 (5), 220-227, 2000
- Non-patent document 6 Proc. Natl. Acad. Sci. USA, 92, 9363-9367, 1995
- Non-patent document 7 Cancer Research, 64, 2956-2961, 2004
- Non-Patent Document 8 Dermatology, 188, 21— 24, 1994
- Non-Patent Document 9 Mol. Cell. Proteomics, 2 (2), 70—84, 2003
- An object of the present invention is to search for a substance that can be a skin aging marker.
- the present inventors focused on cell culture supernatants containing a large amount of a small amount of secreted protein, and performed proteomics of proteins whose expression changes with aging of epidermal keratinocytes. Specifically, the culture supernatants of the second generation (young cells) to the fifth generation (aged cells) of human normal epidermal keratinocytes were prepared, and proteome analysis was performed by two-dimensional electrophoresis and mass spectrometry. Furthermore, as a feature of the present invention, identification was attempted using a technique ⁇ experimental medicine, 20 (16), 2367-2370, 2002 ⁇ that enables identification of ultra-trace protein (below 1 femto-mol).
- a stratum corneum checker capable of non-invasively and safely collecting the stratum corneum from volunteers in their 20s and 60s.
- the stratum corneum was collected using, and the protein was extracted from the stratum corneum, and the expression of the skin aging marker was examined by Western blotting.
- Keratin 7, Keratin 15 and Kallikrein 7 correlate very well with skin elasticity and wrinkle volume ratio, which are known as indicators of skin aging.
- the gist of the present invention is as follows.
- a method for determining the degree of skin aging comprising measuring the expression of secreted protein and Z or intracellular protein in skin cells and Z or skin tissue, and the expression of Z or its gene.
- the above-mentioned method wherein the secreted protein and Z or intracellular protein change in expression due to skin aging.
- a kit for determining the degree of skin aging comprising a secreted protein whose expression is changed by skin aging and an antibody capable of specifically recognizing Z or intracellular protein.
- a kit for determining the degree of skin aging comprising a secreted protein whose expression is changed by skin aging and a nucleic acid probe capable of specifically hybridizing with mRNA of Z or intracellular protein.
- nucleic acid primers that can be specifically and hybridized with mRNAs of Z or intracellular proteins and cDNA synthesized by using the mRNA as a saddle type.
- a method for identifying a substance effective in preventing skin aging comprising the following steps:
- step (b) a step of culturing the skin cells and Z or skin tissue brought into contact with the test substance in step (a) for a predetermined time;
- step (c) Step of measuring the expression of secreted protein and Z or intracellular protein and Z or gene expression thereof in the skin cells and / or skin tissue cultured in step (b), wherein the secreted protein and Z or intracellular A protein whose expression is altered by aging of the skin, and
- step (d) Secreted protein and Z or intracellular protein expression and Z or its gene expression measured in step (c) are compared with secreted protein and Z or intracellular protein expression and Z in control skin cells and Z or skin tissue. Or the evaluation of the expression of secreted protein and Z or intracellular protein in skin cells and Z or skin tissue and the effect of the test substance on Z or its gene expression by comparison with its gene expression Including said method.
- kits for determining the degree of skin aging and methods for identifying substances that are effective in preventing skin aging are also provided.
- Fig. 1 shows changes in proliferation (a) and morphological changes (b) due to passage of epidermal keratinocytes.
- FIG. 2 Stained images of cells stained with SA- ⁇ Gal for each passage number of epidermal keratinocytes (a) and the proportion of cells stained with SA- ⁇ Gal (b) are shown.
- FIG. 3 shows the expression pattern obtained by two-dimensional electrophoretic analysis of the extracted protein at the passage numbers 2 and 5 of the epidermal keratinocytes.
- FIG. 4 shows the results of analysis of Laminin 5 and Fibronectin expression changes associated with aging of epidermal keratinocytes by one-dimensional Western blotting.
- FIG. 5 (a) (b)] shows the results of analysis of changes in the expression of protease and protease inhibitor accompanying senescence of epidermal keratinocytes by one-dimensional Western blotting.
- FIG. 6 shows the results of analysis of heat shock protein expression change by aging of epidermal keratinocytes by one-dimensional Western blotting.
- FIG. 8 shows the results of analysis of changes in the expression of Galectin and IGFBP-3 accompanying senescence of epidermal keratinocytes by one-dimensional Western blotting.
- FIG. 9 shows the results of analysis of changes in Keratin expression associated with aging of epidermal keratinocytes by one-dimensional Western blotting.
- FIG. 10 shows the correlation between the expression of Keratin 15 extracted from the corner of the corner of the eye corner and age.
- FIG. 11 shows the correlation between the expression of Keratin 10 extracted from the corner of the corner of the eye corner and age.
- FIG. 12 shows the correlation between age and eye corner elasticity.
- FIG. 14 shows the correlation between the expression of Kemtin 7 extracted from the corner of the corner of the corner of the eye and elasticity of the corner of the corner of the eye.
- FIG. 15 shows the correlation between expression of Kemtin 15 extracted from the corner of the corner of the corner of the eye and elasticity of the corner of the corner of the eye.
- FIG. 16 shows the correlation between expression of Kemtin 7 extracted from the corner of the corner of the corner of the eye and the volume ratio of the corner of the corner of the corner of the eye.
- FIG. 18 shows the correlation between expression of Kallikrein 7 extracted from the corner of the corner of the corner of the eye and elasticity of the corner of the corner of the eye.
- FIG. 19 The best mode for carrying out the invention showing the correlation between the expression of Kallikrein 7 and the volume ratio of the corner of the corner of the eye
- the present invention provides a method for determining the degree of skin aging, comprising measuring the expression of secreted proteins and Z or intracellular proteins in skin cells and Z or skin tissue.
- Secreted proteins and Z or intracellular proteins change in expression due to skin aging.
- Examples of “expression changes” include changes in the presence or absence of expression of protein and Z or its gene, changes in the expression level, and changes in the ratio of the cleaved and non-cleaved forms of the expressed protein by the protease. Etc.
- Secreted protein and Z or intracellular protein for determining skin aging are Kallikrein 7, P AI-1, uPA, Matriptase, GRP 94, HSP 70, HSP 90, Galectin-1, Galectin-3, Galectin — 7, IGFBP— 3, Enolase— 1, Annexin II, Ezrin, Radixin, Moesin, Gelsolin, Keratin 7, Keratin 10, Keratin 13, Keratin 14, Ke ratin 15, Keratin 16, Keratin 18, Keratin 19, Keratin 20 * 50 ⁇ j8 2- Choose from the group that also has microglobulin power! /. Select one protein May be of multiple types.
- Kallikrein 7 is a secreted protein with a molecular mass of 27,525 Da. It cuts the joints between cells in the stratum corneum and has the function of promoting cell desquamation of the skin surface force. In tissues, it is expressed abundantly in the skin, while expression is observed in the brain, mammary gland, spinal cord and kidney. Remnant S column information (Stratum corneum chymotrytic enzyme, J. ⁇ . Hem. 269: 19420-19426, 1994, L33404). Amino acid sequence information (Kallikrein 7 prec ursor, J. Biol. Chem. 269: 19420-19426, 1994, P49862).
- PAI-l is a secreted protein with a molecular mass of 45,060 Da.
- PAI-1 is an acid-stable glycoprotein and belongs to the serpin family. It is found in plasma, platelets, endothelial cells, hepatocytes, fibrosarcoma cells. Gene sequence information (Plasminogen activator inhibitor—1, J. Clin. Invest. 78: 1673— 1680, 1986, M16006). Amino acid sequence information (Plasminogen activator inhibitor—1, FEBS Lett. 210: 11—16, 1987, P05121).
- uPA is a secreted protein having a molecular mass of 48,525 Da.
- uPA is a type of serine protease that converts plasminogen to plasmin. It is secreted extracellularly as a precursor protein (55 kDa) and becomes a truncated form (35 kDa) and exhibits protease activity. Many expressions are seen in breast cancer.
- Gene sequence information (Urokinase—type plasminogen activator, Nucleic Acids Res. 13: 2759-2771, 1985, BC013575). Amino acid sequence information (Uronase—type plasminogen activator, Hoppe—Seyler's Z. Physiol. Chem. 363: 1043—1058, 1982, P00749).
- GRP94 is a secreted protein with a molecular mass of 92, 469 Da.
- Gene distribution IJ information tumor rejection antigen (gp96) 1, Proc. Natl. Acad. Sci. USA. 87: 5658-5662, 1990, BC066656) Amino acid sequence information (Endoplasmin, Nat. Biotechnol. 21: 566-569, 2003, P14625;>.
- HSP70 is an intracellular protein having a molecular mass of 70, 052 Da. It normally functions as a molecular chaperone in cells and is involved in protein folding, transport, assembly and degradation. The function of HSP70 in mitochondria and ER is to transfer proteins normally. In cooperation with HSP90, it is also involved in intracellular signal transduction. Gene base sequence information (heat shock 70 kDa protein 1A, Immunogenetics 32: 24 2- 251, 1990, BC002453). Amino acid sequence information (Heat shock 70 kDa prote in 1, P08107).
- HSP90 is an intracellular protein having a molecular mass of 85,453 Da. Usually, it plays an important role in the signal transduction system by binding and dissociating to complexes such as steroid hormone receptors. When cells are exposed to high temperatures, HSP90 acts as a molecular chaperone that changes structure and prevents irreversible damage to proteins.
- Gene base sequence information (Heat shoe k protein 90, Nucleic Acids Res. 17: 7108—710, 1989, X15183). Amino acid sequence information (Heat shock protein 90, J. Biol. Chem. 264: 2431-2437, 1989, P07900).
- Galectin-3 is an intracellular protein having a molecular mass of 35,678 Da.
- Gene sequence information (Galectin-3, Proc. Natl. Acad. Sci. USA. 87: 7324-7328, 1 990, AB006780). Amino acid sequence information (Galectin—3, P17931).
- Galectin-7 is an intracellular protein with a molecular mass of 14,944 Da. In general, cell growth is controlled between cells and between cells and extracellular matrix. Apoptosis-related protein controls JNK activity and cytochrome C release. It is also secreted into the cytoplasm, nucleus, and extracellular space. It is a member of the galectin subfamily that was first clawed in human epidermis, and the research ability of cultured epidermal keratinocytes is also unaffected by the degree of stratum corneum, and is expressed in all epidermal cells. Gene sequence information (Galectin—7, Dev. Biol. 168: 259-271, 1995, L07769), amino acid sequence information (Galectin—7, J. Biol. Chem. 270: 5823—5829, 1995, P47929).
- IGFBP-3 is a secreted protein with a molecular mass of 31,660 Da. In general, binding to IGF increases the time to half-life. In cell culture, it inhibits or promotes cell growth. It binds to the IGF receptor on the cell surface. IGFBP-3 has a higher binding strength to IG F-2 than IGF-1. Expression is observed in tissues and almost all tissues. Remnants 1zs il ⁇ Uffr report (Insulin—like growth factor binding protein—3, J. Biol. Chem. 265, 12642—12649, 1990, M35878). Amino acid sequence information (Insulin—like growth factor binding protein—3, J. Biol. Chem. 265, 1 4892-14898, 1990, P17936).
- Enolase-1 is an intracellular protein having a molecular mass of 47,038 Da. 2—phospho
- Annexin II is an intracellular protein with a molecular mass of 38,473 Da. Some have been reported to be secreted extracellularly. A calcium-regulated membrane-bound protein that binds two calcium ions to this protein. It is localized near the cell membrane. Of the two annexin repeats, one binds calcium and one binds phospholipids. This protein crosslinks with actin and cytoskeletal proteins bound to phospholipids in the cell membrane, and activates plasminogen via tPA. Gene base sequence information (Annexin A2, Gene 95: 243-251, 1990, BC015834). Amino acid sequence information (Annexin A2, J. Biol. Chem. 266: 5169-5176, 1991, P07355).
- Ezrin is an intracellular protein with a molecular mass of 69,268 Da.
- the following Radixin and Moe sin are homologous molecules. Mainly functions to connect cytoskeletal proteins to cell membranes. It is located inside the filamentous process called microvilli in the cell membrane. It constitutes the microvil li of intestinal epithelial cells. Phosphorylated by tyrosine kinase. Gene sequence information (Ezrin, J. Biol. Chem. 264: 16727-16732, 1989, X51521). Amino acid sequence information (Ezrin, Biochem. Biophys. Res. Commun. 224: 666— 674, 1996, P15311
- Radixin is an intracellular protein having a molecular mass of 68,564 Da. It mainly functions to connect cytoskeletal proteins and cell membranes. Gene sequence information (Radixin, Genomics 16: 199-206, 1993, L02320). Amino acid sequence information (Radixin, P35241).
- Moesin is an intracellular protein with a molecular mass of 67, 689 Da. It mainly functions to connect cytoskeletal proteins and cell membranes. There is a report that the expression decreases in epidermal keratinocytes with abnormal separation. Gene sequence information (Moesin, Proc. Natl. Acad. Sci. USA. 88: 8297-8301, 1991, M69066). Amino acid sequence information (Moesin, Proc. Natl. Acad. Sci. USA. 88: 8297-8301, 1991, P26038).
- Gelsolin is a secreted protein with a molecular mass of 85, 698 Da. There are two types, one that is secreted outside the cell and the other that works inside the cell. What is secreted extracellularly binds to fibronectin. Gelsolin has three actin polymerization regulation functions: promotion of actin fiber elongation by formation of polymer nuclei, cleavage of the actin fiber, and protection of its ends. Through these dual functions, it controls both aspects of polymerization and depolymerization, and plays an important role in cell motility. Many expressions are seen in platelets and fibroblasts. Genetic information (Gelsolin, Nat. 323, 455-458, 1986, X04412). Amino acid sequence information (Gelsolin, Nat. Biotechnol. 21. 566-569, 2003, P06396).
- Keratin 7 is a cytoskeletal protein having a molecular mass of 51,287 Da and a component of an intermediate filament. Expression is seen in a variety of epithelial cells including glandular cells. It is also expressed in the transitional epithelium, bile duct, lung, and mammary epithelium of the ureter. Some are also used as tumor markers. Gene sequence information (Keratin 7, J. Cell Biol. 107: 1337-1350, 1988, AF50988 7). Amino acid sequence information (Keratin, type II cytoskeletal 7, P08729).
- Keratin 13 is a cytoskeletal protein with a molecular mass of 49,586 Da. It is a component of intermediate filaments that make heterotetramers with keratin 4. Expression is seen in the tongue, esophagus, epithelium, urothelium, etc. Gene sequence information (Keratin 13, Gene 215: 269-279, 199 8, X52426). Amino acid sequence information (Keratin, type I cytoskeletal 13, P13646
- Keratin 14 is a cytoskeletal protein having a molecular mass of 51,490 Da. It is a component of intermediate filaments that form heterotetramers with keratin 5. It is present in the epithelium, especially near the basal layer, where it is often expressed. It is also used as an undivided marker of epithelial system. Gene sequence information (Keratin 14, Proc. Natl. Acad. Sci. USA. 82: 1609 -1613, 1985, BC002690). Amino acid sequence information (Keratin, type I cytoskeleta 1 14, P02533).
- Keratin 15 is a cytoskeletal protein with a molecular mass of 49, 167 Da. It is a component of intermediate filaments. It is mainly located in the epithelial basal layer. Gene sequence information (Keratin 1 5, J. Cell Biol. 106: 1249—1261, 1988, X07696). Amino acid sequence information (Ker atin, type I cytoskeletal 15, P19012).
- Keratin 16 is a cytoskeletal protein with a molecular mass of 51,136 Da. Keratin 6 is a component of intermediate filaments that make heterotetramers. Hair follicle, nail, oral epithelial layer
- Keratin 19 is a cytoskeletal protein with a molecular mass of 44, 106 Da. The smallest molecular weight among keratins. It is a component of the intermediate filament. Usually expressed in most single-layer epithelium and non-keratin type stratified epithelium. It is also expressed in all adenocarcinomas. Gene sequence information (Keratin 19, J. Invest. Dermatol. 92: 707-716, 1989, Y00503). Amino acid coordination IJ information (Keratin, type I cytoskeletal 19, Electrophoresis 13: 9 60-969, 1992, P08727).
- ⁇ 2-microglobulin is a secreted protein with a molecular mass of 13,175 Da. L chain of HLA class I antigen (histocompatibility antigen). It is present on many cell surfaces. It is used as an index for diagnosis of renal dysfunction and various malignant tumors. Some cuts are seen, but their significance is not so clear.
- Gene sequence information (Beta-2-mic roglobulin, J. Immunol. 139: 3132-3138, 1987, AB021288). Amino acid sequence information (Beta-2—microglobulin, Biochemistry 12: 4811—4822 (1973), P61769).
- the protein may be a precursor protein or a mature protein.
- the protein may be a truncated or non-cleavable type.
- Examples of the precursor protein include proprotein and preproprotein.
- Some proproteins and pre-proteins have signal peptides that are characteristic sequences of secreted proteins.
- the expression of secreted protein and Z or intracellular protein in skin cells and Z or skin tissue may be measured, or the gene expression thereof may be measured.
- it can be measured by Northern plot method, PCR method, Western plot method, immunohistochemical analysis method and the like.
- measurement may be performed using a cDNA microarray, ELISA method, antibody array, or the like.
- the expression of secreted protein and Z or intracellular protein in skin cells and Z or skin tissue and the presence or absence of Z or gene expression thereof may be detected, and the expression level may be measured. Also good.
- the presence or absence of the expression of protein and Z or its mRNA can be confirmed by the presence or absence of the appearance of spots or bands at predetermined positions.
- the expression level of protein and Z or its mRNA can be measured by staining intensity of spots and bands. Alternatively, protein and Z or mRNA thereof may be quantified.
- DNA array probe fixed on substrate
- protein chip antibody Use detection methods such as (NATURE REVIEWS, DRUG DISCOVERY, VOLUME 1, SEPTEMBER 20 02, 683—695)
- Luminex NATURE REVIEWS, DRUG DISCOVER Y, VOLUME 1, JUNE 2002, 447—456), etc. Is preferred.
- a skin biopsy sample, or cultured skin cells, cultured skin tissue or the like that can also obtain the force can be used.
- Skin cells include epidermal keratinocytes, dermal fibroblasts, Langerno cells, cells, melanocytes Cell, mast cell, endothelial cell, sebum cell, hair papilla cell, hair matrix cell and the like. Skin cells are supplied from the Human Science Research Resource Bank, RIKEN Cell Bank, and the American Type Culture Collection overseas. You can also purchase Clontech, Kurabo and PromoCell.
- skin force can be collected by a known method (new cell culture experiment method for molecular biology research, p57-71, Yodosha, 1999).
- Examples of the skin tissue include the stratum corneum, epidermis and dermis of the skin.
- Skin tissue can be purchased from Biochain and Super Bio Chips. Further, it can force s harvesting skin force al by a known method (Acta. Derm. Venereol., 85, 389- 393, 2005). Skin models are commercially available from Kurabo Industries Co., Ltd., and TO Sakai Co., Ltd., and these can be used. It can also be prepared by a known method [[. Invest. Dermatol., 104 (1), 107-112,199 5 ⁇ .
- Skin aging refers to the degree of skin aging such as wrinkles and sagging caused by aging. It is clear that wrinkles and sagging progress with aging. In addition, wrinkles, sagging, dullness, and the degree of blotch progression increase as a result of exposure to ultraviolet rays as a result of aging. Wrinkles and sagging can be measured by a known method (Advances and future prospects of evaluation techniques for cosmetics, Cosmetics Association of Japan, Yakuji Nippo, 154- 158, 169-175, 179- 182, 187-190, 2001). In addition, when wrinkles and sagging are formed with aging, it is known that the proliferation ability of skin cells such as epidermal cells and skin fibroblasts decreases in the skin.
- the degree of skin aging can be determined using the decrease in the proliferation ability of skin cells as an index.
- SA— ⁇ -Gal senescence-associated ⁇ -galactosidase
- the degree of skin aging can be determined according to the following criteria.
- the present invention also provides a kit for determining the degree of skin aging.
- the kit of the present invention includes a secreted protein whose expression is changed by skin aging and an antibody capable of specifically recognizing Z or intracellular protein.
- Secreted proteins and / or intracellular proteins are Kallikrein 7, PAI-1, uPA, Matriptase, GRP 94, HSP 70, HSP 90, Galectin-1, Galectin-3, Galectin-7, IGFBP-3, Enolase-1 , Annexin II, Ezrin, Radixin, Moesin, Gelsolin, Keratin 7, Keratin 10, Keratin 13, Keratin 14, Keratin 15, Keratin 16, Keratin 18, Keratin 19, Keratin 20, and j8 2—microglobulin It is preferable.
- Secreted proteins and Z or intracellular proteins are Kallikrein 7, PAI — 1, uPA, Matriptase, GRP 94, HSP 70, HSP 90, Galectin—1, Galectin—3, Galectin—7, IGFBP—3, Enolase— 1 , Annexin II, Ezrin, Radixin, Moesin, Gelsolin, Keratin 7, Keratin 10, Keratin 13, Keratin 14, Ker atin 15, Keratin 16, Keratin 18, Keratin 19, Keratin 20, and j8 2—m icroglobulin force It is preferable to do.
- the kit further includes a tape for collecting skin tissue, reagents for extracting RNA from the skin tissue on the tape, reagents for analyzing RNA by the Northern plot method, instruction manuals, etc. It is okay.
- the instruction manual should include criteria for determining the degree of skin aging.
- the kit of the present invention comprises a secretory protein whose expression is changed by skin aging and a nucleic acid primer capable of specifically hybridizing with mRNA of Z or intracellular protein and said mRNA. It also includes a pair of nucleic acid primers that can also specifically hybridize with cDNA synthesized as a template.
- the kit also includes a tape for collecting skin tissue, reagents for extracting RNA from the skin tissue on the tape, reagents for analyzing RNA by RT-PCR, and instruction manuals. It should be included.
- the instruction manual should include criteria for judging the degree of skin aging.
- the present invention also provides a method for identifying a substance effective in preventing skin aging. This method involves the following steps:
- step (a) contacting the test substance with skin cells and Z or skin tissue; (b) a step of culturing the skin cells and Z or skin tissue brought into contact with the test substance in step (a) for a predetermined time;
- step (c) Step of measuring the expression of secreted protein and Z or intracellular protein in the skin cells and / or skin tissue cultured in step (b), wherein the secreted protein and Z or intracellular protein are caused by skin aging. The process wherein expression is altered, and
- step (d) By comparing the expression of secreted protein and Z or intracellular protein measured in step (c) with the expression of secreted protein and Z or intracellular protein in control skin cells and Z or skin tissue, Evaluating the effect of the test substance on the expression of secreted proteins and Z or intracellular proteins in cells and Z or skin tissue.
- the test substance is V, which may be a protein, peptide, vitamin, hormone, polysaccharide, oligosaccharide, monosaccharide, low molecular weight compound, nucleic acid (DNA, RNA, oligonucleotide, mononucleotide Etc.), lipids, natural compounds other than those mentioned above, synthetic compounds, and mixtures thereof.
- V may be a protein, peptide, vitamin, hormone, polysaccharide, oligosaccharide, monosaccharide, low molecular weight compound, nucleic acid (DNA, RNA, oligonucleotide, mononucleotide Etc.), lipids, natural compounds other than those mentioned above, synthetic compounds, and mixtures thereof.
- the contact between the test substance and the skin cells and Z or skin tissue may be performed by any method, for example, a method of adding the test substance to the culture solution of skin cells and Z or skin tissue, or applying or fixing the test substance. And a method of culturing skin cells and Z or skin tissue on the cultured container or culture sheet.
- a test substance may be applied directly to the skin using a living body such as a human or a non-human mammal (eg, mouse, rat, guinea pig, rabbit, pig, etc.), or a test substance may be orally administered. ⁇ .
- the skin cells and Z or skin tissue to be compared may be the skin cells and Z or skin tissue before contact with the test substance, and the test substance is not contacted! Treated skin cells and Z or skin tissue.
- Secreted proteins and Z or intracellular proteins are Kallikrein 7, PAI-1, uPA, Matriptase, GRP 94, HSP 70, HSP 90, Galectin-1, Galectin-3, Galectin-7, IGFBP-3, Enolase—1, Annexin II, Ezrin, Radixin, Moesin, Gelsolin, Keratin 7, Keratin 10, Keratin 13, Keratin 14, Keratin 15, Keratin 16, Keratin 18, Keratin 19, Keratin 20 and j8 2—from microglobulin Preferred to be selected from the group consisting of:
- Ezrin, Radixin, Moesin, Gelsolin, Keratin 10, Keratin 13, Keratin 14, Keratin 15, Keratin 16, Keratin 18, Keratin 19 and Keratin 2 o expression levels are increased.
- the expression level of these marker proteins is reduced compared to the control, and the test substance strength is evaluated to be effective in reducing the expression of these marker proteins.
- the test substance can be identified as a substance effective in preventing skin aging.
- the expression level of Kallikrein 7, PAI-1, uPA, Matriptase, and Keratin 7 is decreased with the aging of epidermal keratinocytes.
- the expression level of these marker proteins is increased compared to the control, and the test substance has the effect of increasing the expression of these marker proteins. If it can be evaluated, the test substance can be identified as a substance effective in preventing skin aging.
- ⁇ 2 -microglobulin is associated with the aging of epidermal keratinocytes.
- the ratio of non-cleavable to ⁇ 2-microglobulin cleaved compared to the control in skin cells and Z or skin tissue contacted with the test substance increased. If the test substance can be evaluated to be effective in reducing the ratio of the non-cleavable to the cleaved form of j8 2 -microglobulin, this test substance is a substance that is effective in preventing skin aging. Can be identified.
- Normal epidermal keratinocytes were added to serum-free basal medium (KB M, Cambrex Corporation) with factors (0. lng / ml EGF, 0.03 mg / ml bovine pituitary meaium, 5 ⁇ / ml msulin, Using medium KGM (+) supplemented with 0.5 ⁇ / ml hydrocortisone, GA—1000), 37 ° C, 5% CO
- the cells were cultured in a batch. For recovery of culture supernatant (CM; Conditioned medium) and cell extract (CL; Cell lysates), seed cells in 5 x 10 5 cells / 150 mm dish, change medium every 2 days, and until saturation Cultured. For subculture, the cells were seeded in 1 ⁇ 10 5 Z60mm dishes, the medium was changed every two days, and the cells were subcultured when they reached 80% saturation. NHE K can be subcultured to approximately the fifth generation, and was used as an aged cell in the fifth generation in this experiment.
- CM Culture supernatant
- CL Cell lysates
- the dish saturated with NHEK was washed twice with KBM, replaced with KBM and cultured for 1 day to completely remove additional factors.
- the CM was recovered 2 days after the replacement with KBM.
- the collected CM was centrifuged at 130 ⁇ g for 10 minutes to remove floating cells, and then centrifuged at 10,000 ⁇ g for 30 minutes, and the supernatant was collected.
- Ammonium sulfate (Wako Pure Chemical)
- DC protein assay kit (For Bio—Rad Loooratories Inc.) The protein was quantified by Bradford method and used as a sample for Western blotting.
- the prepared CM was lyophilized and dried.
- Sample preparation solution for two-dimensional electrophoresis (6.5M urea (lCN Biomedicals, Inc.), 1.5M thiourea (Sigma Corporation), 0.15% SDS (Wako Pure Chemical Industries, Ltd.), 0. 85% Triton X—100 (Wako Pure Chemical Industries, Ltd.), 0.4% CHAPS (Dojindo Loboratories), 2.5 mM tributyl phosphine (Wako Pure Chemical Industries, Ltd. ) ⁇ And protein was quantified by the dot 'plot method.
- the dish after the CM was collected was washed 3 times with PBS (—) and then frozen at ⁇ 30 ° C. to destroy the cell membrane. Thereafter, the cells were collected using a cell scraper (Sumitomo Bakelite Co., Ltd.) and then sonicated for 30 seconds. After adding 1% Triton X-100, it was left at 4 ° C for 30 minutes. Thereafter, the mixture was centrifuged at 15,000 ⁇ g for 30 minutes to remove insoluble matters, and the supernatant was used as a sample. Protein was quantified by the dot'plot method and used as a sample for Western blotting.
- the first dimension is 20 ° C, 500V—2 hours, 700V—1 hour, 1000V—1 hour, 1500V—1 hour, 2000V—1 hour, 300 0V—1 hour, Isoelectric focusing was performed with a 3500V-10 hour program.
- the gel was equilibrated with SDS equilibration buffer 0.8M urea, 0.0M thiourea, 0.5% dithio thereitol (DTT, Wako Pure Chemical Industries, Ltd.), 25% glycero l (Wako Pure Chemical Industries, Ltd.). , 0.0025% BPB (Wako Pure Chemical Industries, Ltd.) ⁇ and equilibrated at room temperature for 1 hour.
- the second dimension is Tris—Tricine buffer (cathode buffer: 0.05M Tris, 0.05M Tricine (Bio-Rad Loboratories Inc.), 0.05% SDS, anode buffer: 1M Tris—HCl (pH8.8) ) ⁇ was used for SDS-PAGE on a 7.5% acrylamide gel of 18 cm ⁇ 18 cm.
- Transfer buffer is anode 1st solution: 0.3M Tris—HCl (pH 10.4), 20% methanol (Wako Pure Chemical Indus tries, Ltd.), anode 2 solution: 25mM Tris—HCl (pH 10.4), 20% Methanol, negative solution: 25 mM Tris—HCl (pH 10.4), 20% methanol, 40 mM 6-aminohexanoic acid (Wako Pure Chemical Industries, Ltd.) was used.
- Post-transcription [TTBS buffer ⁇ 20 mM Tris—HCl (pH 7.5) (Bio-Rad Loboratories Inc. ), 500 mM NaCKWako Pure Chemical Industries, Ltd.), 0.
- the protease digested solution was diluted 7-fold with distilled water to make the acetonitrile concentration 10%. 2% with 50% acetonitrile Z0. 1% trifluoro-acetic acid (TF A, Wako Pure Chemical Industries, Ltd.) several times to activate the filler part of ZipTipcl8 pipette tips (Millipore Corporation) as pretreatment Acetonitrile / Aspiration was repeated several times with 0.1% TFA. Next, activate the ZipTipcl8 pipette tip. Then, the protease digestion solution was sucked and discharged several times to adsorb the fragmented peptide to the packed portion. Further, 2% acetonitrile ZO. 1% TFA was sucked and discharged several times to remove salts.
- TF A Trifluoro-acetic acid
- SDS-PAGE was performed by Laemmli's Tris-Glycin system using a sample for Western blotting. After SDS-PAGE, after transferring the proteins in the gel to a PVDF membrane (Millipore Corporation) with a constant current of lcm 2 per 0. 8 mA, 5% skim milk ZPBS (-) immersed in, 4 ° C, and blocked with overnight. The PVDF membrane was washed three times with 0.1% Tween20 / PBS (—), then immersed in the primary antibody solution and shaken at room temperature for 1 hour.
- the types and dilution ratios of primary antibodies used are as follows: rabbit anti-maspin polyclonal anti-DO ay (3 ⁇ 4anta and ruz Biotechnology) (1000-fold dilution), mouse anti-cystatin A monoclonal antibody (Sigma ) (1000-fold dilution), rabbit anti— kallikrein 7 polyclonal antibody (Santa Cruz Biotechnology) (1000-fold dilution), sheep anti— PAI— 1 polyclonal antibody (Biopool) (1000-fold dilution), mouse atni— PAI— 2 monoclonal antibody (American Diagnostics) "000-fold dilution), rabbit anti— uPA polyclonal antibody (Santa Cruz Biotec hnology) (1000-fold dilution), rabbit anti-matriptase polyclonal antibody (Ca Ibiochem) (1000-fold dilution), rat anti— GRP94 monoclonal antibody (Stress geen) (1000 times dil
- Keratin 8 monoclonal antibody (Chemicon) (1000 times dilution), mouse anti
- secondary antibodies such as Horseradish peroxidase labeled ami-mouse IgG (Amersham Bioscience buffer diluted 5000 times), Horseradish peroxidase labeled anti-rabbit Ig (Amersham Bioscience) (5000 times) Dilution), Horseradish peroxidase labeled anti-rat IgG (Amersham Bioscience) (5000-fold dilution) or Horseradish peroxidase labeled anti-goat IgG (Santa Cruz) (5000-fold dilution) was used.
- 7 chemiluminescence (ECL) kits (Amersham Bioscience; for detection and detection).
- the expression level of the protein detected by Western blotting was numerically calculated by NIH image, and the value obtained by dividing the expression level of the fifth generation protein by the expression level of the second generation protein was calculated.
- the calculated value is 2.0 or more, it is judged that the expression level has significantly increased with the aging of the epidermal keratinocytes, and when it is less than 0.5, the expression level is significant with the aging of the epidermal keratinocytes. Judged to have decreased.
- the calculated value was 0.5 or more and less than 2.0, it was determined that there was no change in expression accompanying senescence of epidermal keratinocytes.
- cell senescence markers were searched using the second-generation cells as young cells and the fifth-generation cells as senescent cells.
- CMs Second- to fifth-generation CMs were prepared, and proteins whose expression was changed by two-dimensional electrophoresis were analyzed (Figure 3). Comparison of the cell culture supernatant (CM) spots of young (2nd generation) and aged cells (5th generation) revealed that 19 proteins (Table 1) were found to decrease in expression due to cell aging. Forty-nine proteins whose expression increased with aging were identified (Table 2). The identified proteins include known skin aging markers such as Maspin, Cystatin A and HSP 27, and the analysis by two-dimensional electrophoresis performed in this study identifies proteins that change with skin aging. It was considered to be an appropriate method.
- the identified proteins include known skin aging markers such as Maspin, Cystatin A and HSP 27, and the analysis by two-dimensional
- a new skin aging marker protein was identified in addition to the known skin aging marker protein because it used a technology that enables identification of ultra-trace protein (below 1 femto-mol).
- the major secreted proteins whose expression decreased with the aging of epidermal keratinocytes were identified as j8-2 microglobulin, PAI-1 and Kallikrein 7.
- Moesin, Keratin 1 and Keratin 9 were identified as secreted proteins whose expression increased with aging of epidermal keratinocytes.
- Rho GDP d i ssoc iat ion inhibitor Rho-GDI
- Table 2 shows the proteins whose expression increased with the aging of epidermal keratinocytes by two-dimensional electrophoresis analysis.
- Fatty aci d bi nding protein 5 (FAEP 5)
- H3P 70 S.e Heat shock leakage a protein
- HSP 70, HSP 90, and G RP 94 (only GRP 94 has a signal peptide), one of the heat shock proteins that are intracellular proteins, are frequently secreted into CM with aging.
- the level of expression in CL was unchanged (Fig. 6).
- Enolase-1 an glycolytic enzyme in the cell
- Annexin II that binds to phospholipids in the cell membrane
- EzrinZMoesinZRadixin a cytoskeletal protein
- Keratin 3 13 types of Keratin, a cytoskeletal protein (Keratin 3, 5, 7, 8, 10, 1 3, 14, 15, 16, 17, 18, 19 and 20).
- Keratin 10 13 types of Keratin 10, 13, 14, 15, 16, 18, 19, and 20 increased significantly with the aging of epidermal keratinocytes (Fig. 9).
- the expression of keratin 7 in cells was significantly decreased with the aging of epidermal keratinocytes (Fig. 9). Keratin 3, 5, 8, and 17 did not change expression. Keratins were not detected in CM.
- Table 3 summarizes the proteins whose expression changes with the aging of epidermal keratinocytes by one-dimensional Western blotting analysis.
- Table 3 shows the proteins whose expression was changed with the aging of epidermal keratinocytes by one-dimensional Western blotting analysis.
- the stratum corneum was peeled from the corner of the eye using the stratum corneum checker (Asahibiomed Co., Ltd.), and the protein was extracted using the protein extraction solution. Specifically, a stratum corneum was applied to the subject's eyes and rubbed lightly with the fingertips. This was repeated three times. After that, 50 1 protein extraction solutions OmM Tris-HCl (pH 7.5), 120 mM NaCl, 0.4% Igepal CA-630 (Sigma-Aidrich Co.) ) ⁇ , The stratum corneum was acclimated to the protein extraction solution using a cell scraper, and the solution was collected in a 1.5 ml plastic tube (Eppendorf AG).
- Centrifugation was performed at 10,000 Xg for 15 minutes to precipitate insoluble matter, and the supernatant was collected in a new 1.5 ml plastic tube. The amount of protein in the collected sample was measured using a DC assay kit.
- Detection was carried out by Western blotting using the Keratin 7, Keratinl5 and Kallikrein 7 antibodies described in Example 1, using 10 / z g of protein extracted from the corner of the corner of the corner of the eye. The intensity of the detected band was measured with a densitometer (Molecular Dinamics Co., Ltd.) and numerically calculated with NIH image.
- Keratin 10 As for Keratin, it is clear that the expression of Keratin 10 decreases with skin aging. Therefore, Keratin 10, Keratin 7 and Keratin 15 have a correlation with any kind of Keratin strength in human skin aging. I checked if there was. As a result of examining the correlation between the age of Keratin 10 and Ker atin 15, Keratin 10 was not correlated with age, and Keratin 15 was correlated with age. It became clear that it is a more appropriate skin aging marker than the best (see Fig. 10). And Figure 11).
- proteins whose expression increases or decreases with cellular senescence and proteins that change to uncut form can be expected to be applied to cosmetic counseling systems as diagnostic markers for skin aging. It is also expected to develop more effective cosmetics and health foods using the expression of these proteins as an index.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007532124A JP5362219B2 (ja) | 2005-08-23 | 2006-08-22 | 皮膚老化マーカーとその利用技術 |
CN200680031061.8A CN101248192B (zh) | 2005-08-23 | 2006-08-22 | 皮肤老化标记物及其利用技术 |
US12/064,602 US7972788B2 (en) | 2005-08-23 | 2006-08-22 | Skin aging marker and technique for use thereof |
KR1020087005901A KR101318521B1 (ko) | 2005-08-23 | 2006-08-22 | 피부 노화 마커와 그의 이용기술 |
HK08110309.7A HK1114883A1 (en) | 2005-08-23 | 2008-09-17 | Skin aging marker and technique for use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005240820 | 2005-08-23 | ||
JP2005-240820 | 2005-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007023808A1 true WO2007023808A1 (ja) | 2007-03-01 |
Family
ID=37771551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/316407 WO2007023808A1 (ja) | 2005-08-23 | 2006-08-22 | 皮膚老化マーカーとその利用技術 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7972788B2 (ja) |
JP (4) | JP5362219B2 (ja) |
KR (1) | KR101318521B1 (ja) |
CN (1) | CN101248192B (ja) |
HK (1) | HK1114883A1 (ja) |
WO (1) | WO2007023808A1 (ja) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007259851A (ja) * | 2006-03-02 | 2007-10-11 | Fancl Corp | 皮膚老化の検査方法 |
JP2008178390A (ja) * | 2006-12-27 | 2008-08-07 | Nippon Menaade Keshohin Kk | 皮膚の状態を評価する方法及びその用途 |
JP2009008607A (ja) * | 2007-06-29 | 2009-01-15 | Fancl Corp | 皮膚色素沈着マーカーとその利用技術 |
WO2009123224A1 (ja) * | 2008-03-31 | 2009-10-08 | 独立行政法人国立病院機構 | 老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法 |
FR2929518A1 (fr) * | 2008-04-04 | 2009-10-09 | Oreal | Utilisation cosmetique de proteines de type annexine ii pour le traitement du vieillissement cutane |
FR2929517A1 (fr) * | 2008-04-04 | 2009-10-09 | Oreal | Utilisation cosmetique de proteines de type annexine ii pour le traitement de la secheresse cutanee |
JP2009276336A (ja) * | 2008-04-14 | 2009-11-26 | Kao Corp | 毛穴目立ち予防又は改善剤評価方法 |
WO2010053254A1 (en) * | 2008-11-07 | 2010-05-14 | Amorepacific Corporation | A method of screening material for improving skin functions |
JP2010115131A (ja) * | 2008-11-12 | 2010-05-27 | Kao Corp | 肌評価方法及び皮膚老化改善剤・皮膚老化予防剤のスクリーニング方法 |
WO2010073983A1 (ja) * | 2008-12-24 | 2010-07-01 | 株式会社ファンケル | シワ形成リスク評価方法 |
WO2011000833A1 (en) * | 2009-06-30 | 2011-01-06 | Universitätsklinikum Heidelberg | Gene signature for replicative senescence in cell cultures |
JP2011185811A (ja) * | 2010-03-10 | 2011-09-22 | Fancl Corp | 皮膚角質層のタンパク質測定方法 |
KR101098940B1 (ko) | 2009-04-06 | 2011-12-28 | 대한민국 | 발암물질에 대한 바이오마커로서 moesin |
JP2012501183A (ja) * | 2008-08-28 | 2012-01-19 | ダームテック インターナショナル | 皮膚サンプルの年齢範囲の決定方法 |
JP2012073267A (ja) * | 2011-11-21 | 2012-04-12 | Fancl Corp | 皮膚色素沈着マーカーとその利用技術 |
JP2013541960A (ja) * | 2010-10-29 | 2013-11-21 | 株式會社アモーレパシフィック | Klotho遺伝子を含む皮膚活性物質探索用キット及びこれを利用して皮膚活性物質を探索する方法 |
CN103808940A (zh) * | 2012-11-02 | 2014-05-21 | 株式会社芳珂 | 粗糙肌肤的评价方法 |
US9057109B2 (en) | 2008-05-14 | 2015-06-16 | Dermtech International | Diagnosis of melanoma and solar lentigo by nucleic acid analysis |
JP2017020833A (ja) * | 2015-07-08 | 2017-01-26 | 国立大学法人 熊本大学 | 皮膚状態の評価方法 |
JP2020502498A (ja) * | 2016-11-25 | 2020-01-23 | ユニヴェルシテ グルノーブル アルプス | ヒトの皮膚の老化の新規バイオマーカー |
US11578373B2 (en) | 2019-03-26 | 2023-02-14 | Dermtech, Inc. | Gene classifiers and uses thereof in skin cancers |
US11976332B2 (en) | 2018-02-14 | 2024-05-07 | Dermtech, Inc. | Gene classifiers and uses thereof in non-melanoma skin cancers |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101248192B (zh) * | 2005-08-23 | 2013-02-20 | 株式会社芳珂 | 皮肤老化标记物及其利用技术 |
KR101612906B1 (ko) | 2008-07-23 | 2016-04-19 | 한국과학기술원 | 피부에 가한 역학 자극의 스크리닝 방법 |
JP4473926B1 (ja) * | 2008-12-24 | 2010-06-02 | 株式会社ファンケル | 紫外線による皮膚黒化傾向の評価方法 |
AU2011237664A1 (en) * | 2010-04-06 | 2012-10-25 | National Foundation For Fertility Research | Secretome profile-facilitated in vitro fertilization |
KR101409610B1 (ko) * | 2010-07-13 | 2014-06-20 | (주)아모레퍼시픽 | 피부 진단 방법 및 키트 |
KR101886342B1 (ko) * | 2010-11-30 | 2018-08-10 | (주)아모레퍼시픽 | 피부 노화와 관련된 유전자 및 피부 노화를 방지하는 물질을 스크리닝하는 방법 |
JP5658696B2 (ja) * | 2011-02-25 | 2015-01-28 | 株式会社ファンケル | 皮膚のストレス蓄積度の評価方法 |
KR102027451B1 (ko) | 2012-11-02 | 2019-10-02 | (주)아모레퍼시픽 | 마이크로 rna 및 이를 사용하는 스크리닝 방법 |
JP6182728B2 (ja) * | 2012-11-02 | 2017-08-23 | 国立大学法人名古屋大学 | 幹細胞を標的とした薬効及び毒性の評価法 |
JP6609401B2 (ja) * | 2014-06-16 | 2019-11-20 | 株式会社ファンケル | カリクレイン7産生促進剤 |
JP6530646B2 (ja) * | 2015-06-22 | 2019-06-12 | 株式会社ファンケル | 頭皮の圧縮応力の評価方法 |
KR20170076484A (ko) | 2015-12-24 | 2017-07-04 | 삼성전자주식회사 | 프로토카데린의 과발현을 이용한 노화 세포를 분리하는 방법 |
JP6993076B2 (ja) * | 2015-12-24 | 2022-01-13 | ポーラ化成工業株式会社 | 皮下組織構造の改善成分のスクリーニング方法 |
KR101971358B1 (ko) * | 2016-09-26 | 2019-04-23 | 동국대학교 산학협력단 | 검버섯 진단용 마커로서의 구아닌 탈아미노효소의 용도 |
CN106906180A (zh) * | 2016-12-28 | 2017-06-30 | 里程 | 一种具有生物活化作用的复合添加剂及其制备方法和用途 |
JP6923111B2 (ja) * | 2017-02-27 | 2021-08-18 | ポーラ化成工業株式会社 | 皮膚老化改善剤のスクリーニング方法 |
WO2019026918A1 (ja) * | 2017-08-01 | 2019-02-07 | 株式会社国際電気通信基礎技術研究所 | 皮膚のバイオマーカー |
CN109839507A (zh) * | 2017-11-27 | 2019-06-04 | 江苏坤辉生物科技有限公司 | 一种检测紫外光损伤的生物标志物及其应用 |
CN112272775A (zh) * | 2018-06-04 | 2021-01-26 | 雅芳产品公司 | 用于鉴定和治疗衰老皮肤和皮肤病症的蛋白生物标志物 |
JP7016102B2 (ja) * | 2018-12-06 | 2022-02-04 | キリンホールディングス株式会社 | T細胞又はnk細胞の製造方法、t細胞又はnk細胞の培養用培地、t細胞又はnk細胞の培養方法、未分化t細胞の未分化状態を維持する方法及びt細胞又はnk細胞の増殖促進剤 |
WO2021036807A1 (zh) * | 2019-08-26 | 2021-03-04 | 中国科学院上海营养与健康研究所 | 一类小rna分子及其类似物在抗衰老中的应用 |
WO2024085637A1 (ko) * | 2022-10-18 | 2024-04-25 | 동국대학교 산학협력단 | 혈장 유래 단백질을 포함하는 노화 방지용 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002511240A (ja) * | 1998-04-15 | 2002-04-16 | ライフスパン バイオサイエンシーズ, インコーポレイテッド | 薬物に関連した核酸配列およびタンパク質 |
WO2002074911A2 (en) * | 2001-03-19 | 2002-09-26 | Wisconsin Alumni Research Foundation | Identification of gene expression alterations underlying the aging process in mammals |
WO2004005462A2 (en) * | 2002-07-03 | 2004-01-15 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of tumor senescence genes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001212087A (ja) | 2000-01-31 | 2001-08-07 | Axiom Co Ltd | 肌年齢算出装置および肌年齢算出方法 |
JP4413387B2 (ja) * | 2000-07-12 | 2010-02-10 | 丸善製薬株式会社 | コラーゲン産生促進剤、エラスターゼ活性阻害剤、コラゲナーゼ活性阻害剤及び皮膚化粧料 |
JP2002277455A (ja) * | 2001-03-15 | 2002-09-25 | Shiseido Co Ltd | 皮膚老化因子検出組成物及び検出方法 |
JP4575619B2 (ja) | 2001-05-08 | 2010-11-04 | ポーラ化成工業株式会社 | 実年齢の推定方法 |
JP4681760B2 (ja) | 2001-06-06 | 2011-05-11 | ポーラ化成工業株式会社 | 顔形状の加齢変化の推定法 |
US20030026794A1 (en) * | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
JP3863462B2 (ja) * | 2002-06-24 | 2006-12-27 | 株式会社資生堂 | 皮膚疾患および敏感肌の検査方法ならびにその方法に利用するキット |
CN101248192B (zh) * | 2005-08-23 | 2013-02-20 | 株式会社芳珂 | 皮肤老化标记物及其利用技术 |
-
2006
- 2006-08-22 CN CN200680031061.8A patent/CN101248192B/zh active Active
- 2006-08-22 KR KR1020087005901A patent/KR101318521B1/ko not_active IP Right Cessation
- 2006-08-22 US US12/064,602 patent/US7972788B2/en not_active Expired - Fee Related
- 2006-08-22 WO PCT/JP2006/316407 patent/WO2007023808A1/ja active Application Filing
- 2006-08-22 JP JP2007532124A patent/JP5362219B2/ja not_active Expired - Fee Related
-
2008
- 2008-09-17 HK HK08110309.7A patent/HK1114883A1/xx unknown
-
2012
- 2012-04-27 JP JP2012103365A patent/JP5596742B2/ja not_active Expired - Fee Related
-
2013
- 2013-04-26 JP JP2013093746A patent/JP5663054B2/ja not_active Expired - Fee Related
-
2014
- 2014-02-25 JP JP2014033492A patent/JP2014149299A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002511240A (ja) * | 1998-04-15 | 2002-04-16 | ライフスパン バイオサイエンシーズ, インコーポレイテッド | 薬物に関連した核酸配列およびタンパク質 |
WO2002074911A2 (en) * | 2001-03-19 | 2002-09-26 | Wisconsin Alumni Research Foundation | Identification of gene expression alterations underlying the aging process in mammals |
WO2004005462A2 (en) * | 2002-07-03 | 2004-01-15 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of tumor senescence genes |
Non-Patent Citations (23)
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007259851A (ja) * | 2006-03-02 | 2007-10-11 | Fancl Corp | 皮膚老化の検査方法 |
JP2008178390A (ja) * | 2006-12-27 | 2008-08-07 | Nippon Menaade Keshohin Kk | 皮膚の状態を評価する方法及びその用途 |
JP2009008607A (ja) * | 2007-06-29 | 2009-01-15 | Fancl Corp | 皮膚色素沈着マーカーとその利用技術 |
WO2009123224A1 (ja) * | 2008-03-31 | 2009-10-08 | 独立行政法人国立病院機構 | 老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法 |
WO2009136033A3 (fr) * | 2008-04-04 | 2010-04-29 | L'oreal | Utilisation cosmetique de proteines de type annexine ii pour le traitement de la secheresse cutanee |
FR2929518A1 (fr) * | 2008-04-04 | 2009-10-09 | Oreal | Utilisation cosmetique de proteines de type annexine ii pour le traitement du vieillissement cutane |
FR2929517A1 (fr) * | 2008-04-04 | 2009-10-09 | Oreal | Utilisation cosmetique de proteines de type annexine ii pour le traitement de la secheresse cutanee |
JP2009276336A (ja) * | 2008-04-14 | 2009-11-26 | Kao Corp | 毛穴目立ち予防又は改善剤評価方法 |
US11753687B2 (en) | 2008-05-14 | 2023-09-12 | Dermtech, Inc. | Diagnosis of melanoma and solar lentigo by nucleic acid analysis |
US11332795B2 (en) | 2008-05-14 | 2022-05-17 | Dermtech, Inc. | Diagnosis of melanoma and solar lentigo by nucleic acid analysis |
US10407729B2 (en) | 2008-05-14 | 2019-09-10 | Dermtech, Inc. | Diagnosis of melanoma by nucleic acid analysis |
US9057109B2 (en) | 2008-05-14 | 2015-06-16 | Dermtech International | Diagnosis of melanoma and solar lentigo by nucleic acid analysis |
JP2012501183A (ja) * | 2008-08-28 | 2012-01-19 | ダームテック インターナショナル | 皮膚サンプルの年齢範囲の決定方法 |
JP2016019531A (ja) * | 2008-08-28 | 2016-02-04 | ダームテック インターナショナル | 皮膚サンプルの年齢範囲の決定方法 |
AU2009285645B2 (en) * | 2008-08-28 | 2015-11-19 | Dermtech International | Determining age ranges of skin samples |
WO2010053254A1 (en) * | 2008-11-07 | 2010-05-14 | Amorepacific Corporation | A method of screening material for improving skin functions |
CN102209790A (zh) * | 2008-11-07 | 2011-10-05 | 株式会社爱茉莉太平洋 | 筛选用于改善皮肤功能的材料的方法 |
JP2012508006A (ja) * | 2008-11-07 | 2012-04-05 | アモーレパシフィック コーポレイション | 皮膚機能向上用材料のスクリーニング方法 |
JP2010115131A (ja) * | 2008-11-12 | 2010-05-27 | Kao Corp | 肌評価方法及び皮膚老化改善剤・皮膚老化予防剤のスクリーニング方法 |
JP2010151480A (ja) * | 2008-12-24 | 2010-07-08 | Fancl Corp | シワ形成リスク評価方法 |
KR101074230B1 (ko) | 2008-12-24 | 2011-10-14 | 가부시키가이샤환케루 | 주름 형성 리스크 평가방법 |
WO2010073983A1 (ja) * | 2008-12-24 | 2010-07-01 | 株式会社ファンケル | シワ形成リスク評価方法 |
KR101098940B1 (ko) | 2009-04-06 | 2011-12-28 | 대한민국 | 발암물질에 대한 바이오마커로서 moesin |
EP2302381A1 (en) * | 2009-06-30 | 2011-03-30 | Ruprecht-Karls-Universität Heidelberg | Gene signature for replicative senescence in cell cultures |
WO2011000833A1 (en) * | 2009-06-30 | 2011-01-06 | Universitätsklinikum Heidelberg | Gene signature for replicative senescence in cell cultures |
JP2011185811A (ja) * | 2010-03-10 | 2011-09-22 | Fancl Corp | 皮膚角質層のタンパク質測定方法 |
JP2013541960A (ja) * | 2010-10-29 | 2013-11-21 | 株式會社アモーレパシフィック | Klotho遺伝子を含む皮膚活性物質探索用キット及びこれを利用して皮膚活性物質を探索する方法 |
JP2012073267A (ja) * | 2011-11-21 | 2012-04-12 | Fancl Corp | 皮膚色素沈着マーカーとその利用技術 |
CN103808940A (zh) * | 2012-11-02 | 2014-05-21 | 株式会社芳珂 | 粗糙肌肤的评价方法 |
JP2017020833A (ja) * | 2015-07-08 | 2017-01-26 | 国立大学法人 熊本大学 | 皮膚状態の評価方法 |
JP2020502498A (ja) * | 2016-11-25 | 2020-01-23 | ユニヴェルシテ グルノーブル アルプス | ヒトの皮膚の老化の新規バイオマーカー |
JP7115756B2 (ja) | 2016-11-25 | 2022-08-09 | ユニヴェルシテ グルノーブル アルプス | ヒトの皮膚の老化の新規バイオマーカー |
US11976332B2 (en) | 2018-02-14 | 2024-05-07 | Dermtech, Inc. | Gene classifiers and uses thereof in non-melanoma skin cancers |
US11578373B2 (en) | 2019-03-26 | 2023-02-14 | Dermtech, Inc. | Gene classifiers and uses thereof in skin cancers |
Also Published As
Publication number | Publication date |
---|---|
KR101318521B1 (ko) | 2013-10-16 |
KR20080057233A (ko) | 2008-06-24 |
JP5663054B2 (ja) | 2015-02-04 |
US7972788B2 (en) | 2011-07-05 |
JPWO2007023808A1 (ja) | 2009-02-26 |
CN101248192A (zh) | 2008-08-20 |
JP2012189602A (ja) | 2012-10-04 |
JP2014149299A (ja) | 2014-08-21 |
HK1114883A1 (en) | 2008-11-14 |
CN101248192B (zh) | 2013-02-20 |
JP5362219B2 (ja) | 2013-12-11 |
JP5596742B2 (ja) | 2014-09-24 |
US20090305242A1 (en) | 2009-12-10 |
JP2013174608A (ja) | 2013-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007023808A1 (ja) | 皮膚老化マーカーとその利用技術 | |
US7820396B2 (en) | Method for determining atopic dermatitis using protein marker | |
Liu et al. | Proteomic analysis on the alteration of protein expression in the placental villous tissue of early pregnancy loss | |
Roop et al. | Transcriptional control of high molecular weight keratin gene expression in multistage mouse skin carcinogenesis | |
Lanoix et al. | Stability of reference proteins in human placenta: general protein stains are the benchmark | |
TWI434039B (zh) | 以鱗狀細胞癌抗原為指標之皮膚性狀評估方法 | |
WO2009081374A2 (en) | Cosmetic use of plakoglobin-type proteins | |
Yamashiro et al. | Ectopic coexpression of keratin 8 and 18 promotes invasion of transformed keratinocytes and is induced in patients with cutaneous squamous cell carcinoma | |
US20200072851A1 (en) | Method of diagnosis of the aesthetic qualities of the skin | |
BR112013014575B1 (pt) | Uso in vitro ou ex vivo, processo in vitro ou ex vivo e processo cosmético in vitro ou ex vivo | |
JP7115756B2 (ja) | ヒトの皮膚の老化の新規バイオマーカー | |
Byrjalsen et al. | Human endometrial proteins with cyclic changes in the expression during the normal menstrual cycle: characterization by protein sequence analysis | |
US10060931B2 (en) | Use of complex forms of calmodulin-like skin protein CLSP | |
JP4971055B2 (ja) | 皮膚色素沈着マーカーとその利用技術 | |
JP2010164404A (ja) | シワ形成マーカーとその利用方法 | |
JP5542110B2 (ja) | 皮膚色素沈着マーカーとその利用技術 | |
WO2003086176A2 (en) | Observation of effects of body fluids on indicator cells for disease diagnosis | |
Liang et al. | The differential expression of aqueous soluble proteins in breast normal and cancerous tissues in relation to ethnicity of the patients; Chinese, Malay and Indian | |
Giergiel et al. | Comparison between endometrial protein profile in Holstein-Friesian heifers and female prepubertal calves | |
JP5700727B2 (ja) | 皮膚色素沈着マーカーとその利用技術 | |
JP5563710B2 (ja) | 皮膚色素沈着マーカーとその利用技術 | |
Alhumidi | Hereditary epidermolysis bullosa in Saudi Arabia, epidemiological, pathological, ultrastructural study of fourteen patients. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680031061.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007532124 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12064602 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087005901 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06796621 Country of ref document: EP Kind code of ref document: A1 |